Physician profile
John A Tenini
NPI 1184915043
$1,380.33
in general payments reported to CMS, 2019-2025
25 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $195 · 2024: $74.48 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $279.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $177.25 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.32 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $99.26 | 2019-2025 | Airsupra |
| Sumitomo Pharma America, INC. | $76.82 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $57.06 | 2024-2025 | Shingrix, Arexvy |
| Pfizer INC. | $56.19 | 2019-2020 | |
| Gilead Sciences, INC. | $51.41 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.24 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $40.71 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $35.27 | 2019-2020 | |
| Esperion Therapeutics, INC. | $32.78 | 2020 | |
| Exact Sciences Corporation | $32.22 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $27.44 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $27.33 | 2025 | Omnipod |
| Tandem Diabetes Care, INC. | $25.64 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $25.15 | 2025 | |
| Lilly USA, LLC | $24.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $23.10 | 2025 | Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $21.35 | 2025 | Eliquis |
| Abbott Laboratories | $21.16 | 2025 | Freestyle Libre 3 |
| Nevro Corp. | $20.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.97 | 2019 | |
| Shire North American Group INC | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tenini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.